|2.||Human Influenza (Influenza)
|5.||Marek Disease (Marek's Disease)
|1.||Suarez, David L: 35 articles (04/2015 - 04/2002)|
|2.||Swayne, David E: 33 articles (07/2015 - 11/2005)|
|3.||Spackman, Erica: 29 articles (07/2015 - 09/2002)|
|4.||Katz, Jacqueline M: 26 articles (07/2015 - 01/2004)|
|5.||Kawaoka, Yoshihiro: 23 articles (05/2015 - 04/2004)|
|6.||Chen, Hualan: 23 articles (04/2015 - 05/2003)|
|7.||Mettenleiter, Thomas C: 23 articles (01/2015 - 03/2006)|
|8.||Webster, Robert G: 21 articles (01/2016 - 02/2002)|
|9.||Subbarao, Kanta: 21 articles (10/2015 - 05/2003)|
|10.||Veits, Jutta: 20 articles (01/2015 - 03/2006)|
07/01/2010 - "The present study in BALB/c mice was conducted to compare immunogenicity and protective efficacy of several candidate vaccines based on homologous and heterologous strains after challenge with the highly pathogenic avian influenza strain A/Chicken/Kurgan/3/2005. "
04/06/2009 - "This study investigates the safety, immunogenicity and efficacy of different pox-vector vaccines expressing the haemagglutinin of a highly pathogenic (HP) H5N1 avian influenza virus (AIV) (A/chicken/Indonesia/7/03) in pigs. "
10/09/2013 - "Suboptimal protection against H5N1 highly pathogenic avian influenza viruses from Vietnam in ducks vaccinated with commercial poultry vaccines."
12/01/2012 - "Several global outbreaks of highly pathogenic avian influenza (HPAI) H5N1 virus have increased the urgency of developing effective and safe vaccines against H5N1. "
09/01/2010 - "A safe and effective adjuvant is important to develop vaccines against highly pathogenic avian influenza virus. "
01/06/2000 - "This recombinant fowlpox-H5 avian influenza hemagglutinin vaccine can provide protection against a variety of different highly pathogenic H5 avian influenza viruses and frequent optimizing of the hemagglutinin insert to overcome genetic drift in the vaccine may not be necessary to provide adequate field protection."
12/01/2003 - "Construction, genetic stability and protective efficacy of a recombinant fowlpox virus expressing hemagglutinin (HA) gene (rFPV-HA) of H5 subtype avian influenza virus were conducted. "
12/01/2003 - "[Construction, genetic stability and protective efficacy of recombinant fowlpox virus expressing hemagglutinin gene of H5N1 subtype avian influenza virus]."
12/01/2015 - "The results of the study shows that avian influenza viruses after multiple passages in different biological systems undergo mutations, in particular, the largest number of amino acid substitutions occurred in all biological substrates in the hemagglutinin. "
01/01/2015 - "In this study we demonstrated that the vaccine candidate against avian influenza virus H5N1 based on the hemagglutinin H5 (HA) fused to the chicken CD154 (HACD) can also be used for differentiating infected from vaccinated animals (DIVA). "
|3.||DNA (Deoxyribonucleic Acid)IBA
05/19/2006 - "The result showed that immunization once with not less than 10microg or twice with 3microg HA-DNA or NA-DNA provided effective protection against homologous avian influenza H9N2 virus."
03/01/2010 - "Protective efficacy of H7 subtype avian influenza DNA vaccine."
07/26/2011 - "In this study, M2e sequence was fused to H1N1 HA DNA (M2e-HA) and the immunogenicity and antiviral efficacy of this DNA vaccine was evaluated in response to challenge with a heterosubtypic H5N2 avian influenza virus. "
09/01/2012 - "Improved immune responses against avian influenza virus following oral vaccination of chickens with HA DNA vaccine using attenuated Salmonella typhimurium as carrier."
05/01/2011 - "Strategies for improving the efficacy of a H6 subtype avian influenza DNA vaccine in chickens."
|4.||Influenza Vaccines (FluMist)IBA
04/01/2009 - "Efficacy of a commercial inactivated H5 influenza vaccine against highly pathogenic avian influenza H5N1 in waterfowl evaluated under field conditions."
01/01/2009 - "This, along with the ominous threat of an avian influenza pandemic (H5N1), demonstrates the need for a much improved, more sophisticated influenza vaccine. "
07/01/2014 - "We used African green monkeys (AGMs) as a nonhuman primate (NHP) model for a comprehensive and comparative evaluation of pairs of wild-type and pandemic live attenuated influenza virus vaccines (pLAIV) representing four subtypes of avian influenza viruses and found that pLAIVs replicate similarly in AGMs and humans and that AGMs can be useful for evaluation of the protective efficacy of pLAIV."
11/12/2014 - "In this study, we evaluated a potential live influenza vaccine candidate using an H7N3 avian influenza virus isolated from ducks with controls of two recombinant viruses generated through reverse genetics. "
01/01/2014 - "Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine."
06/17/2010 - "Results provide evidence of effectiveness of attenuated Salmonella strains for delivery of recombinant avian influenza HA antigens and induction of mucosal and systemic immune responses protective against lethal challenge with HPAI."
01/01/2014 - "In the present study, we report characterization of a conserved truncated protein, potentially a universal influenza virus antigen from the H5N1 Highly Pathogenic Avian Influenza A virus strain. "
07/01/2011 - "In this study, we constructed a recombinant (pgsA-HA1 gene fusion) Lactococcus lactis strain that expresses and displays the avian influenza virus HA1 antigens on its surface. "
05/01/2011 - "The objective of this study was to test the ability of chicken CD154 to enhance the immunogenicity of an adenoviral vector-based vaccine against avian influenza virus in order to reduce the amount of antigen required to induce an effective immune response in avian. "
03/15/2011 - "In the present study, we developed an antigen capture enzyme-linked immunosorbent assay (AC-ELISA) to detect serum sCD25 in ducks, and we used flow cytometry (FCM) to analyze the frequency of CD25(+) cells in the peripheral blood of ducks infected with H9N2 or H5N1 avian influenza virus (AIV) or serotype II Riemerella anatipestifer (RA). "
01/01/2011 - "We have identified and characterized an H5N1 neuraminidasespecific monoclonal antibody which specifically inhibits N1 neuraminidase activity of highly pathogenic avian influenza (HPAI) strains from clades 1 and 2. We have also shown the protective efficacy of this antibody in animal challenge models using homologous virus. "
04/01/2014 - "In this study, the neuraminidase (NA) gene of three Avian Influenza (AI) H9N2 strains isolated from poultry farms in Iran during 2010-11, as well as other reported Iranian H9N2 isolates, were genetically analyzed and their nucleotide changes were evaluated. "
01/01/2013 - "In this study, 9 pairs of primers were designed with PrimerHunter and successfully used to differentiate the 9 neuraminidase (NA) genes of avian influenza viruses (AIVs) in multiple PCR-based assays. "
03/15/2012 - "Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus."
06/20/2011 - "High-throughput neuraminidase substrate specificity study of human and avian influenza A viruses."
|7.||Proteins (Proteins, Gene)IBA
01/01/2013 - "For these reasons, we investigated the efficacy of an inactivated H9N2 virus vaccine (a-H9N2) mixed with M2e (1xM2e or 4xM2e) proteins expressed in Escherichia coli, which contains the consensus of sequence the extracellular domain of matrix 2 (M2e) of A/chicken/Vietnam/27262/09 (H5N1) avian influenza virus, and investigated its humoral immune response and cross-protection against influenza A viruses. "
03/01/2007 - "Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1."
02/01/2015 - "While M2 has previously been shown to protect avian influenza virus HA proteins of the H5 and H7 subtypes that have polybasic cleavage motifs, this study demonstrates that M2 can protect HA proteins from human H1N1 strains that lack a polybasic cleavage motif. "
01/01/2015 - "This study supported the fact that the ELISA assays using the proteins NP49-375 and HACD could be valuable tools for avian influenza surveillance and as a strategy of DIVA for counteracting the highly pathogenic avian influenza virus H5N1 outbreaks. "
03/01/2011 - "In this study, we achieved type/subtype of avian influenza virus (AIV) within 5 h, based on 4 major proteins, by significantly reducing ion suppression and signal overlap from various protein sources. "
|8.||Oseltamivir (Tamiflu)FDA Link
07/01/2007 - "Avian influenza A viruses in birds of the order Psittaciformes: reports on virus isolations, transmission experiments and vaccinations and initial studies on innocuity and efficacy of oseltamivir in ovo."
12/01/2011 - "Antiviral efficacy of oseltamivir against avian influenza virus in avian species."
10/09/2007 - "Oseltamivir (Tamiflu) is now being stockpiled by several governments as a first line treatment for an anticipated outbreak of avian influenza caused by H5N1. "
03/01/2012 - "This study showed that oseltamivir-resistant N6 NA avian influenza viruses are rare, and must be tested both phenotypically and genotypically to confirm resistance."
05/01/2011 - "Study of specific oligosaccharide structures related with swine flu (H1N1) and avian flu, and tamiflu as their remedy."
05/12/2011 - "Protective efficacy of H5 inactivated vaccines in meat turkey poults after challenge with Egyptian variant highly pathogenic avian influenza H5N1 virus."
10/16/2007 - "In the face of disease outbreaks in poultry and the potential pandemic threat to humans caused by the highly pathogenic avian influenza viruses (HPAIVs) of H5N1 subtype, improvement in biosecurity and the use of inactivated vaccines are two main options for the control of this disease. "
03/01/2009 - "Chitozan is a perspective adjuvant for inactivated vaccines against avian influenza viruses, which could significantly improve immune response and protective efficacy against both homologous and drifted variants of avian influenza viruses A/H5."
02/15/2011 - "Clinical studies have indicated that subvirion inactivated vaccines against avian influenza viruses, particularly H5N1, are poorly immunogenic in humans. "
03/01/2010 - "The aim of this study was to evaluate the level of protection afforded by MDA against challenge with highly pathogenic avian influenza virus (HPAIV), and its suspected interference with current inactivated vaccines in broilers under controlled laboratory conditions. "
|10.||Antiviral Agents (Antivirals)IBA
06/01/2007 - "Nucleic acid-based antiviral drugs are promising classes of experimental antiviral drugs that have been shown in pre-clinical studies to be effective against seasonal and avian influenza viruses. "
01/01/2007 - "Although hostellers responded positively to hand washing advice provided in the travel health lecture, reinforcement of other possible measures to prevent avian influenza, particularly the possible role of antiviral drugs, may be needed."
02/01/2006 - "(9) Efficacy of antiviral drugs on avian influenza (bird flu) was studied during a 2003 Dutch outbreak due to a type A/H7N7 virus. "
06/24/2014 - "Monitoring the in vivo dynamics of avian influenza viruses is extremely important for understanding viral pathogenesis and developing antiviral drugs. "
01/01/2014 - "The present paper provides an overview of the recent advances in the design of new antiviral drugs against avian influenza. "
04/25/2008 - "The post-exposure therapeutic efficacy of injectable peramivir against highly pathogenic avian influenza type A H5N1 was evaluated in mice and in ferrets. "
09/01/1983 - "Twenty-four acute myelogenous leukemia (AML) patients in first clinical remission received, as a part of their maintenance therapy, repeated injections of viral oncolysate (i.e., avian influenza virus-infected, formalin-inactivated, allogeneic leukemia cells). "
01/01/2007 - "Holistic efficacy of specific nutrient synergy against avian flu virus: pathology and immunomodulation."
06/01/2013 - "Cytokine dysregulation has been observed in patients with severe influenza, such as avian influenza A (H5N1) and pandemic 2009 influenza A (H1N1pdm09) virus infections, but the role of immunomodulatory therapy is unclear, due to lack of data from randomized controlled trials (RCTs). "
11/01/2007 - "One intraperitoneal injection of 100 or 400 mcg of HSP induced rapid protection against intraperitoneal challen e with 125 LD50 of Salmonella typhimurium (on 3rd-6th day) and against intranasal challenge with 10 LD50 of avirulent for humans avian influenza virus H5N2 (A/ mallard/Pennsylvania/10218/84) (on 5th-8th day). "
|5.||Quantum Dots (Quantum Dot)
10/01/2015 - "Rapid and Quantitative Detection of Avian Influenza A(H7N9) Virions in Complex Matrices Based on Combined Magnetic Capture and Quantum Dot Labeling."
10/15/2012 - "A fast and sensitive immunoassay of avian influenza virus based on label-free quantum dot probe and lateral flow test strip."
11/01/2010 - "Quantum-dots-based fluoroimmunoassay for the rapid and sensitive detection of avian influenza virus subtype H5N1."
07/09/2014 - "In this work, we use quantum dots to label avian influenza H9N2 virus and elaborate on the infection mechanism of the virus in human bronchial epithelial (HBE) cells using a three-dimensional SPT technique. "
02/01/2010 - "In the present study, we report a novel separation-free method to detect and quantify avian influenza virus A (H5N1) nucleic acid without amplification, based on the alteration of photophysical parameters of quantum dot (QD) probes after hybridization with specific complementary target DNA. "